TNFRSF4 and cancer: More recently, agonistic OX40 agents have been deployed in early-stage clinical trials either alone or in combination with CPI treatment in solid tumors.42 43 Given that OX40 has been identified as potentially enriched in certain types of irAE-affected tissue, it will be important to maintain a high level of clinical vigilance to determine whether agonists of this pathway can alter the severity and type of irAEs that develop in patients with cancer.